Skip to content

Gastric Cancer Prevention for Indigenous Peoples

A Gastric Cancer Prevention Program for Aboriginal People Living in the Remote Areas

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03900910
Enrollment
50000
Registered
2019-04-03
Start date
2018-01-01
Completion date
2030-12-31
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Cancer prevention, Antibiotics, Inequality

Brief summary

The incidence of gastric cancer in local indigenous peoples is higher than the non-Indigenous counterpart in Taiwan. How to design an effective prevention strategy for gastric cancer is of importance. The present study aimed to identify the causes that may account for the health inequalities, allowing generation of a plan of action on the whole population scale.

Detailed description

Owing to the continuing gap in cancer burden between Indigenous and non-Indigenous peoples, reducing health disparities has drawn worldwide attention. Evidence indicates that the gastric cancer incidence and mortality rates in Indigenous peoples are much higher than those of non-Indigenous counterparts living in the same areas. Exposure to more risk factors from social habits, lifestyle, and Helicobacter pylori infection has been considered the cause. However, even though gastric cancer has been repeatedly shown to be preventable by eliminating risk factors, eradication policies are rarely designed for Indigenous peoples. Possible obstacles may include the lack of Indigenous health statistics, inadequate access to care, difficulty in modifying social habits and lifestyles, and the presence of environmental and cultural barriers. Developing and implementing a preventive strategy following the evidence-based principle remains a challenge. In Taiwan, the number of Indigenous peoples has grown; however, their life expectancy remains substantially lower than that of the non-Indigenous population. Cancer is the most prevalent cause of death for Indigenous peoples and a disproportionate prevalence of certain kinds of cancer is noted for Indigenous peoples. These observations provide an opportunity to establish a plan of action, in which a specific intervention is developed to decrease the threat from each specific cancer so that the overall disparate burden can be reduced in a stepwise manner.

Interventions

OTHERGastric cancer prevention

Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.

OTHERExecution of the program

Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER
Ministry of Health and Welfare, Taiwan
CollaboratorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Mass screening and eradication of Helicobacter pylori infection in Indigenous community.

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 20-60 years * Mentally competent to be able to understand the consent form * Able to communicate with study staff for individuals

Exclusion criteria

* Pregnancy * Individuals with major comorbid diseases

Design outcomes

Primary

MeasureTime frameDescription
Gastric cancer incidenceAfter at least 5 years, the gastric cancer incidence per 100,000 person-years is calculated by the person-years of follow-up.To assess the effect of H. pylori eradication for gastric cancer prevention
Helicobacter eradication rateAt least 5 yearsTo assess the eradication rate of anti-H. pylori treatment.
The participation rateScreening program quality indicatorThe number of participants divided by the number of invitees
The positivity rateScreening program quality indicatorThe number of positive test results divided by the number of participants
The referral-to-treatment rateScreening program quality indicatorThe number of individuals who received anti-H pylori treatment divided by the number of positive test results
The reinfection rateScreening program quality indicatorThe number of positive test results divided by the person-years of follow-up

Countries

Taiwan

Contacts

CONTACTYi-Chia Lee, MD, PhD
yichialee@ntu.edu.tw886-2-23123456
PRINCIPAL_INVESTIGATORYi-Chia Lee, MD, PhD

National Taiwan University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026